Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors - 14/04/20
Funding sources: Supported in part by the Joan and Irwin Jacobs Fund and by National Cancer Institute grant P30 CA016672 (to Dr Kurzrock). |
|
Disclosure: Dr Kurzrock has received research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols, and Guardant Health; consultant fees from Merck, Pfizer, Roche, X-Biotech, and Actuate Therapeutics; and speaker fees from Roche; holds an ownership interest in CureMatch, Inc; and serves on the Board of CureMatch and CureMetrix, Inc. Dr Cohen has no conflicts of interest to declare. |
|
IRB approval status: Not applicable. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?